The optimal antithrombotic strategy and duration to mitigate peri-procedural and long-term thrombotic and bleeding events after transcatheter aortic valve implantation remain unclear.
What is the optimal antithrombotic strategy and duration to mitigate thrombotic and bleeding risks in patients undergoing transcatheter aortic valve implantation?
This review outlines current insights and ongoing trials aimed at determining the optimal antithrombotic strategy following TAVI to balance thrombotic and bleeding risks.
Transcatheter aortic valve implantation (TAVI) has emerged as a valuable treatment alternative to surgical aortic valve replacement among patients with symptomatic aortic stenosis at increased surgical risk. The rapid technological evolution from early to current-generation TAVI systems with low-profile delivery catheters, bioprosthetic valves with proven midterm durability, and improved positioning and retrieval features have made important contributions to the widespread clinical use of this minimal invasive therapy. Although peri-procedural and long-term thrombotic and bleeding events after TAVI remain a relevant concern, the optimal antithrombotic strategy and duration to mitigate these risks remain unclear. This review provides an overview of recent insights in this field, and highlights current and future antithrombotic trials focusing on optimizing outcomes in patients undergoing TAVI.
Vranckx et al. (Thu,) conducted a review in Symptomatic aortic stenosis. Antithrombotic therapy was evaluated. The optimal antithrombotic strategy and duration to mitigate peri-procedural and long-term thrombotic and bleeding events after transcatheter aortic valve implantation remain unclear.